1/ Some #melanoma posters and talks I'm excited to learn more about at @ASCO 2018:
#uveal 1 year OS 74% in @Immunocore Ph1b expansion of IMCgp100 (disclosure: I'm on ad board) meetinglibrary.asco.org/record/162309/…
2/ #uveal modest activity with BET inhibition as monotherapy
meetinglibrary.asco.org/record/158612/…
and
meetinglibrary.asco.org/record/160188/…
3/ #mucosal important Phase 3 of adjuvant platinum-based chemo vs interferon:
meetinglibrary.asco.org/record/162094/…
Cisplatin + temozolomide mPFS 15 mo, mOS 40 mo - not too much worse than the Phase 2 data. Should chemo be standard adjuvant therapy?
4/ #mucosal tantalizing Ph2 data of combined VEGF/TKI + PD1 inhibition from same Beijing group:
meetinglibrary.asco.org/record/163540/…
among 24 eval pts, 12 responses, 10 ongoing. ?follow up but nice rationale to explore this field
5/ injectables! in #melanoma:
e.g. TLR + ipi in PD-1 refractory tumors
meetinglibrary.asco.org/record/159086/…
TLR + PD-1 in tx-naive group
meetinglibrary.asco.org/record/161517/…
Stage IIIB-IV path CR rate of just 12 weeks of T-VEC is 20%
meetinglibrary.asco.org/record/161758/…
6/ impressive neoadjuvant activity of nivo+ipi, but PD-1 alone risks losing surgical window...
meetinglibrary.asco.org/record/159091/…
7/ and obviously, the #IDO post-mortem:
meetinglibrary.asco.org/record/159087/…
perhaps the biopsy cohort on indoximod Ph2 can shed some light...
meetinglibrary.asco.org/record/159088/…
8/ and perhaps most importantly, a bevy of PD-1 resistance talks across #melanoma #lcsm etc etc that I'm not smart enough to sort through in advance...e.g. a cohort from our Australian colleagues:
meetinglibrary.asco.org/record/159094/…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.